Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.44 |
| ▸ | LIPE | Q05469 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 3/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15012086 | 1.00 | NR1H2 (0.49) | NR1H2DDB1CRBNLIPEUSP30 | |
| SCHEMBL19272699 | 1.00 | NR1H2 (0.49) | NR1H2DDB1CRBNLIPEUSP30 | |
| SCHEMBL23361057 | 0.87 | GPR119 (0.45) | NR1H2DDB1CRBNLIPEKDM4E | |
| SCHEMBL31213542 | 0.87 | GPR119 (0.48) | DDB1CRBNLIPEKDM4EGPR119 | |
| SCHEMBL29693973 | 0.87 | GPR119 (0.45) | NR1H2DDB1CRBNLIPEKDM4E | |
| SCHEMBL23361204 | 0.87 | GPR119 (0.48) | DDB1CRBNLIPEKDM4EGPR119 | |
| SCHEMBL24510956 | 0.87 | GPR119 (0.45) | NR1H2DDB1CRBNLIPEKDM4E | |
| SCHEMBL24510347 | 0.87 | GPR119 (0.45) | NR1H2DDB1CRBNLIPEKDM4E | |
| SCHEMBL24509732 | 0.87 | GPR119 (0.45) | NR1H2DDB1CRBNLIPEKDM4E | |
| SCHEMBL29076899 | 0.87 | GPR119 (0.45) | NR1H2DDB1CRBNLIPEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317735-A1 | HYDROISOQUINOLINE OR HYDRONAPHTHYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2024-09-26 | — | — | US | disclosed |
| CN-118574834-A | Fused tetracyclic compounds, compositions and uses thereof | 泰博生物科技股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240140958-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | TABOMEDEX BIOSCIENCES INC (US) | 2024-05-02 | — | — | US | disclosed |
| EP-4310089-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| EP-4274833-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4182032-A1 | HYDROISOQUINOLINE OR HYDRONAPHTHYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022150707-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, Inc. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022013136-A1 | HYDROISOQUINOLINE OR HYDRONAPHTHYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2022-01-20 | — | — | WO | disclosed |
| EP-3416960-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| US-10640498-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-05 | — | — | US | disclosed |
| US-20190055232-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| EP-3416960-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017141036-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED (GB) | 2017-08-24 | — | — | WO | disclosed |
| US-9309252-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2016-04-12 | — | — | US | disclosed |
| EP-2536730-B1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2015-07-08 | — | — | EP | disclosed |
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2015-04-09 | — | — | US | disclosed |
| US-8957074-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640498-B2 | Compounds | USP30, USP20, UBQLN1 | NR1H2 2112/4885DDB1 357/4885CRBN 558/4885 |
| US-20240317735-A1 | HYDROISOQUINOLINE OR HYDRONAPHTHYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HRH3, H1-3, HRH4 | NR1H2 1048/4885DDB1 2230/4885CRBN 4139/4885 |
| US-20190055232-A1 | NOVEL COMPOUNDS | USP30, USP20, USP28 | NR1H2 2402/4885DDB1 353/4885CRBN 547/4885 |
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | NR1H2 3981/4885DDB1 586/4885CRBN 1291/4885 |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | NR1H2 3976/4885DDB1 635/4885CRBN 1232/4885 |
| US-20240140958-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | NR1H2 703/4885DDB1 3939/4885CRBN 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.